Drug repurposing is transforming the landscape of rare disease treatment by leveraging existing medications for new uses. With significantly lower development costs and faster timelines, this approach is gaining traction—especially when supported by natural history studies that provide deep insights into disease progression and real-world treatment patterns.
The EMA’s August 2025 guidance on embryo-foetal risk minimisation marks a pivotal step in harmonizing safety protocols across the EU. This blog breaks down the new Addendum I to GVP Module XVI, clarifying what constitutes a Pregnancy Prevention Programme and how risk minimisation tools can be effectively implemented without compromising patient access to essential treatments.
Dr. Janine Collins
Vice President, Medical, Scientific & Real-World Research
Instability is woven into our industry’s DNA. We operate daily in a high-stakes, high-risk environment where financial pressures, regulatory changes, and patient lives hang in the balance. The CRO selection process reflects this tension, few other sectors require competitors to both challenge and collaborate with one another, often for the same client. Our ecosystem is […]
Learn about the FDA's new guidance, the challenges of standardization, and how UBC is driving innovation in REMS implementation using modern APIs from UBC's VP of Data Intelligence and Program Analytics, Jim Shamp.
Discover UBC's insights from the Cell & Gene Meeting on the Mesa, the unique challenges patients face, and the importance of tailored support services to ensure successful treatment journeys
In the realm of pharmaceuticals, regulatory compliance is paramount to ensure patient safety. With the complex environment of safety reporting, several vendors may be involved at global and local levels for performing submission activities to health authorities, ethics committees and investigators. Director of UBC Global Case Processing, Myrto Ioannidi and UBC Team Manager, Esther Aparicio review […]
Lorem ipsum dolor sit amet consectetur. Mi proin enim ipsum nascetur. Venenatis odio scelerisque non netus ac et pellentesque.
Service Request
Bekki Bracken Brown
President & Chief Executive Officer
Bekki Bracken Brown serves as the President and CEO of UBC, guiding the company’s mission and values, including the improvement of access for patients to receive better outcomes. She oversees all aspects of UBC, such as operations, business growth strategy, sales and marketing, and acquisition support.
With over 20 years of industry experience, Ms. Brown brings knowledge from a successful career in senior management from her tenure at Quintiles, INC Research, and, most recently, with Syneos Health. She’s been a member of the North Carolina BIO Board of Directors since 2019. She is also a member of the Healthcare Businesswomen’s Association — Southeast Chapter and CHIEF, an organization that supports women executive leaders. Ms. Brown earned her bachelor’s degree at Duke University.